Nippon Shokubai Co. Ltd. ADS (NPSHY) Financials Oct 28,

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Nippon Shokubai Co. Ltd. ADS (NPSHY) Financials Oct 28, 2014, 3:00 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Nippon Shokubai Co. Ltd. ADS


Fiscal year is April-March. All values JPY millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 244.32B 288.35B 320.7B 269.52B 302.14B
Cost of Goods Sold (COGS) incl. D&A 196.43B 221.8B 252.3B 224.87B 252.7B
COGS excluding D&A 180.05B 205.71B 235.05B 209B 235.71B
Depreciation & Amortization Expense 16.38B 16.09B 17.25B 15.87B 17B
Depreciation - - - - -
Amortization of Intangibles - - - - -
Gross Income 47.89B 66.54B 68.4B 44.65B 49.43B
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 34.57B 37.07B 37.61B 34.95B 36.06B
Research & Development 10.75B 11.25B 11.94B 11.44B 11.16B
Other SG&A 23.81B 25.83B 25.67B 23.51B 24.9B
Other Operating Expense 0 0 0 0 0
Unusual Expense 807M 875M (214M) 1.05B (202M)
EBIT after Unusual Expense (807M) (875M) 214M (1.05B) 202M
Non Operating Income/Expense 1.65B 226M 613M 3.34B 1.78B
Non-Operating Interest Income 145M 98M 84M 85M 123M
Equity in Affiliates (Pretax) 1.04B 2.35B 2.35B 1.37B 1.11B
Interest Expense 1.22B 874M 735M 674M 599M
Gross Interest Expense 1.22B 874M 735M 674M 599M
Interest Capitalized 0 0 0 0 0
Pretax Income 14.13B 30.4B 33.33B 12.78B 15.98B
Income Tax 3.15B 8.99B 11.62B 4.22B 5.12B
Income Tax - Current Domestic 2.33B 9.99B 11.78B 3.34B 5.49B
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic 821M (1B) (158M) 872M (373M)
Income Tax - Deferred Foreign - - - - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates - - - - -
Other After Tax Income (Expense) - 0 0 0 0
Consolidated Net Income 10.97B 21.41B 21.71B 8.56B 10.87B
Minority Interest Expense 142M 294M 450M 159M 363M
Net Income 10.83B 21.12B 21.26B 8.4B 10.5B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 10.83B 21.12B 21.26B 8.4B 10.5B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 10.83B 21.12B 21.26B 8.4B 10.5B
EPS (Basic) 60.85 110.30 104.71 41.38 51.74
Basic Shares Outstanding 178.01M 191.48M 203M 203M 202.98M
EPS (Diluted) - 110.30 104.71 41.38 51.74
Diluted Shares Outstanding - 191.48M 203M 203M 202.98M
EBITDA 29.7B 45.56B 48.05B 25.57B 30.37B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading